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Weekly Subcutaneous Pegylated Recombinant Native
Human Leptin (PEG-OB) Administration in Obese Men
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Jersey 07110; and Department of Food Science and Human Nutrition, Colorado State University
(F.J.S., L.A.C.), Fort Collins, Colorado 80523
ABSTRACT
To assess the biological activity and tolerability of pegylated re-
combinant native human leptin (PEG-OB), 30 obese men (mean body
mass index, 33.9 kg/m2) were randomized to a double-blind treatment
with weekly sc injections of 20 mg PEG-OB or placebo for 12 weeks,
in addition to a hypocaloric diet (deficit, 2 MJ/day). Body composition,
energy expenditure, and metabolic parameters were measured before
and after treatment. PEG-OB was generally well tolerated based on
adverse event reports, lab values, and vital signs. Weekly sc PEG-OB
led to sustained serum concentrations of PEG-OB and leptin through-
out treatment. No significant differences in the delta or percent
weight loss, percent body fat, sleeping metabolic rate, or respiratory
quotient were observed between the PEG-OB and placebo groups.
Percent change in serum triglycerides from baseline was significantly
correlated with body weight loss in the PEG-OB group, but not in the
placebo group. Although larger reductions in serum triglycerides were
observed in the PEG-OB group compared with the placebo group,
these differences were not statistically significant. We concluded that
weekly injection of PEG-OB leads to sustained serum concentration
of PEG-OB and leptin throughout the 12-week treatment period and
is generally well tolerated. The trends observed in serum triglycerides
suggest that a weekly 20-mg sc treatment with PEG-OB may have
biological effects in obese men. (J Clin Endocrinol Metab 85: 4003–
4009, 2000)
OBESITY IS A complex, increasingly prevalent and im-portant health problem throughout the world (1). Hu-
man obesity is characterized by increased adipose tissue
mass resulting from a complex interaction of genetic pre-
disposition to metabolic efficiency and environmental/
lifestyle factors (2–5). Obese individuals are at increased risk
for conditions such as noninsulin-dependent diabetes mel-
litus, hypertension, hyperlipidemia, coronary heart disease,
stroke, and certain cancers (1). Although treatment [e.g.
healthy eating (including behavior modification), physical
activity, drugs] is available and most people can achieve
medically significant weight loss (5–10% initial body
weight), the long-term maintenance of that weight loss and
its associated improvement in health is, unfortunately, very
rare (2–4). These factors and the psychological, social, and
economic costs of obesity are matters of growing concern in
the scientific, medical, and public health communities (1).
New scientific information concerning the regulation of
energy balance and fat mass has emerged since the discovery
of leptin (also known as OB protein). Evidence from many
animal studies and observational studies in humans suggests
that this hormone, which is secreted primarily from adipo-
cytes in proportion to cell size, seems to play a role in the
control of body fat stores by acting within the central nervous
system to coordinate the regulation of feeding behavior,
metabolism, autonomic nervous system, and body energy
balance in rodents, primates, and humans (4–6). Although
obese individuals have increased serum concentrations of
leptin (7, 8) and concomitant decreased sensitivity to leptin,
therapeutic augmentation of the circulating leptin levels, by
administration of leptin, may result in increased leptin sig-
naling and action in a manner similar to use of exogenous
insulin to increase insulin signaling in noninsulin-dependent
diabetes mellitus (4, 5). Thereby, reductions of food intake,
body fat mass, and body weight in obese patients may result
from treatment with recombinant leptin.
Since its identification, interest within the medical commu-
nity in the effects (if any) of treatment of obese individuals with
leptin has been significant (4). However, only initial interven-
tional studies in humans are available to support these sug-
gestions. In trials sponsored by Amgen Inc., significant dose-
related reductions in body fat and body weight (up to 27.1 kg
in the highest dose group) were observed following daily sc
treatment with from 0.01–0.30 mg/kg recombinant human
met-leptin for 24 weeks in obese subjects (9). In the treatment
of a young very obese girl with a mutated ob gene, daily sc
injection of low doses of met-leptin (dose of 0.028 mg/kg of lean
mass calculated to cause a circulating concentration ;10% of
what would be predicted based on her body fat) has been
reported. Daily met-leptin treatment caused a dramatic reduc-
tion in appetite, food-seeking behavior, food intake, and body
weight (10). The results of treatment of this girl with congenital
leptin deficiency (10), taken together with the results of the
clinical trials in obese adults (9), indicate that leptin has bio-
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logical activity in at least some obese humans and that among
its activities are reductions in appetite and food intake at low
doses and reductions in body fat and body weight at the max-
imal dose studied.
Leptin has been reported to have a very short apparent half-
life in animals (11, 12) and humans (13). Polyethylene glycols
(PEG) are amphiphilic polymers of ethylene glycol with vary-
ing average molecular weights that can be activated and co-
valently attached to proteins. Modification of proteins through
pegylation, covalent linkage of PEG polymers to the protein,
has resulted in increased serum half-life and reduced immu-
nogenicity for a number of proteins (14–16). This technology
was applied to leptin to produce pegylated recombinant native
human leptin or PEG-OB protein (PEG-OB), which was used in
this study. Preclinical studies with PEG-OB indicate an ex-
tended half-life in rodents (.48 h) compared with that reported
for recombinant native human leptin (data not shown) and
efficacy for reduction of food intake and body weight of rats
treated daily with sc PEG-OB for 8 days (17, 18).
We undertook a double blind, randomized study to de-
termine the biological activity and safety of elevating serum
levels of leptin using PEG-OB in comparison with placebo in
obese men on a mild hypocaloric diet.
Subjects and Methods
Experimental subjects
This single center trial had a prospective, randomized double blind
placebo-controlled group design. This study was conducted according
to the guidelines for Good Clinical Practice and was monitored by
Hoffmann-La Roche, Inc. (Welwyn, UK).
Obese [body mass index (BMI), $27.0 kg/m2] men 18–60 yr of age were
eligible for inclusion. Recruitment was from the Institute waiting list or by
local advertising. All aspects of the study conformed to the declaration of
Helsinki. The ethics committee of the University of Maastricht approved the
study, and all participants gave written informed consent. Patients with
obesity-related diseases requiring pharmacological treatment (e.g. diabetes,
hypertension, dyslipidemia) were excluded. Other exclusion criteria were:
weight loss more than 3 kg in the previous 3 months; presence of any
significant illness, including laboratory or electrocardiogram abnormalities;
history or presence of drug abuse or alcoholism; and smoking more than
five cigarettes or equivalent per day. Also, known allergy, history of atopy
or hypersensitivity to pegylated proteins, and use of any drug that might
have influenced body weight or serum lipids led to exclusion.
Study design
After screening, 30 patients were selected and enrolled. Baseline
energy expenditure, body composition, and metabolic profile (including
lipid profile and insulin sensitivity) were measured. Patients were strat-
ified and matched into pairs according to age, BMI, and serum leptin and
insulin concentrations to achieve balanced treatment groups. Random-
ization numbers for patients were generated and incorporated into the
double blind labeling by a third party. During the treatment period,
either an injection of 20 mg PEG-OB (2 mL, 10 mg/mL21) or placebo (2
mL) were given sc, in the para-umbilical region, weekly for 12 weeks.
In addition, all subjects were prescribed a hypocaloric diet (500 kcal or
2 MJ/day deficit). The energy content of the diet was based on the
measured energy expenditure of each subject (see below). The dietary
prescription was discussed every 2 weeks with a dietitian. Subjects came
to the laboratory in the morning, in a fasting state, each week to receive
treatment. Vital signs and body weight were recorded, and blood sam-
ples were taken for standard laboratory tests. At the end of the 12-week
treatment period, energy expenditure, body composition, and metabolic
profile were measured again.
Measurements of energy expenditure and body composition
Energy expenditure and substrate utilization were measured during
a 36-h stay in a respiration chamber while the subjects were maintained
in energy balance by adjusting the food provided (19). Macronutrient
composition of the diet was fixed at 45/15/40% of energy for carbo-
hydrate, protein, and fat, respectively. The respiration chamber is a 14
m2 room furnished with a bed, chair, wash bowl, toilet, and radio/TV
set and telephone. While in the chamber, subjects had to follow a stan-
dardized physical activity program, including controlled exercise for 35
min on a bicycle ergometer (starting at 40 W for 5 min, followed by 80
W for 30 min). Two exercise sessions took place; one in the morning at
1000 h and the other one in the afternoon at 1500 h. Gas sampling and
analysis from the chamber is described in detail elsewhere (20).
Total energy expenditure, sleeping metabolic rate (SMR), and respi-
ratory quotient (RQ) were calculated during the last 24 h in the chamber.
Energy expenditure was calculated from the O2 consumption and CO2
production according to the method of Weir (21). SMR was calculated
from the sleep period between 0300 and 0600 h, controlled for physical
activity by a Doppler radar system. Body weight was measured (with
a calibrated digital scale accurate to 0.01 kg), and height was measured
to the nearest 0.001 m. Body composition was determined after leaving
the respiration chamber in the morning by using hydrodensitometry and
deuterium dilution (22). Body composition was calculated using the
combined equation of Siri (23).
Blood chemistry and pharmacokinetics
Fasting serum concentrations of glucose, insulin, free fatty acids,
glycerol, triglycerides, total cholesterol, and high-density lipoprotein
(HDL) cholesterol were measured at baseline (day 1) and after 12 weeks
of treatment (day 85). Samples were stored at 280 C and analyzed by
a certified laboratory. Low-density lipoprotein (LDL) cholesterol was
calculated using the Friedewald equation (24).
Insulin sensitivity was assessed by the short insulin tolerance test (25).
After an overnight fast, sampling and injection catheters were placed.
Arterialized venous blood samples were collected after insulin was iv
injected (Human Actrapid; Novo Nordisk A/S, Bagsvaerd, Denmark;
0.1 U kg21 body weight). The test was terminated after 16 min by an iv
glucose injection. The rate constant for plasma glucose disappearance
(Kitt) was calculated using a linear regression line fitted through the
blood glucose values from 4–16 min because no changes in blood glu-
cose were noted within 4 min after insulin injection.
Fasting blood samples for the measurement of serum concentrations
of leptin and PEG-OB were collected weekly before the next dosing and
analyzed at Hoffman-La Roche Inc. (Nutley, NJ). For the pharmacoki-
netics of leptin and PEG-OB, a frequent sampling schedule was applied
in weeks 1 and 12. Serum leptin concentrations were measured using a
double-antibody “sandwich” enzyme-linked immunosorbent assay
using a monoclonal antibody specific for human leptin. The lower level
of detection is 0.5 ng/mL, and the upper limit is 50 ng/mL. The intra-
and interassay variations were 9% and 12%, respectively. The leptin
levels of normal weight subjects ranged from 2–12 ng/mL. PEG-OB
concentrations were measured using a similar enzyme-linked immu-
nosorbent assay after separating PEG-OB from leptin by size exclusion.
Quality control samples covering a range of leptin and PEG-OB con-
centrations were included in each assay. Both assays were verified by
appropriate recovery and cross-reaction experiments.
Safety
Safety of PEG-OB was monitored during each visit by documentation
of adverse events and the recording of vital signs on Case Report Forms.
Routine clinical hematology and biochemical tests and urine analysis
were done weekly.
PEG-OB
Recombinant native human leptin, expressed and purified from Esch-
erichia coli, was chemically conjugated to a species of branched PEG
molecule with an average molecular weight of 42 kD in a 1:1 ratio. The
result was a globular PEG—native human leptin polymer with increased
molecular size (26, 27). PEG-OB at a concentration of 10 mg/mL was
placed in sterile glass vials containing 1.3 mL.
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Statistical analysis
The number of subjects needed was calculated as follows. Results of
clinical trials using a hypocaloric diet and orlistat treatment (120 mg
t.i.d.) for 12 weeks reported weight loss in 1022 placebo-treated subjects
as 2.23 kg with a sd of 3.04 kg (Roche orlistat protocols 14119B, M14119,
M14149, M14161, and M14185). With this information, power calculation
indicated that 25 subjects per treatment group were needed to detect an
additional weight reduction in the PEG-OB group of 4.0 kg over that seen
in the placebo group with a power of 90%, assuming a sd of 3 kg.
Assuming a 20% dropout rate, 30 subjects per treatment group would
be required. This number of subjects was also sufficient to detect a
difference in change from baseline SMR between the groups of 0.21 kJ
per min with a power of 90%. This calculation was based on a sd of SMR
in a single subject of 0.16 kJ per min with an estimated SMR of 5.3 kJ per
min, accordingly to the WHO equation (28). However, after the first 30
subjects completed the study, a planned interim analysis was conducted
and the study of weekly 20-mg sc PEG-OB was prematurely stopped by
the sponsor due to lack of efficacy for weight loss at the dose tested.
Changes from baseline after 12 weeks of treatment were compared
between the PEG-OB-treated and placebo group using factorial
ANOVA. Post hoc, for each comparison separately, ANOVA with re-
peated measures was used. Additional statistical tests were used when
appropriate. All statistical tests were two-sided, and significance was
defined as P , 0.05. All data are presented as mean 6 sem, unless
otherwise indicated.
Results
Of the 38 subjects screened, 8 did not meet the inclusion
criteria. The initial demographic characteristics of the sub-
jects are shown in Table 1. The characteristics of the 15 sub-
jects randomized to each treatment group were similar. All
30 subjects who were randomized into the two treatment
groups completed the trial.
Serum concentrations of PEG-OB and leptin
Serum concentrations of PEG-OB during the study are
shown in Fig. 1. Following weekly sc dosing, sustained se-
rum levels of PEG-OB, measured just before the next dose,
ranging from 200–300 ng/mL, were observed. The PEG-OB
serum profile after sc injection was similar after the first (day
1) and 12th weekly (day 78) dose (Fig. 1). Following a sc
injection, mean peak serum PEG-OB concentrations were
achieved 72 h after dosing, followed by a return to the ele-
vated pre-dose levels after 1 week.
Baseline total leptin concentrations during the study are
shown in Fig. 2. Baseline total leptin concentrations were
20.4 6 4.9 and 21.9 6 4.9 ng/mL (mean 6 sem) in the placebo
FIG. 1. Serum levels of PEG-OB follow-
ing weekly sc dosing during the study.
PEG-OB was administered sc on days 1,
8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and
78. PEG-OB concentrations are mean 6
SD. More frequent blood sampling oc-
curred after the first (day 1) and 12th
weekly (day 78) dose. Note the sus-
tained blood levels of PEG-OB in sam-
ples taken just before the next weekly
dose of PEG-OB throughout the study;
these sustained PEG-OB levels ranged
from 200–300 ng/mL. Note that the
PEG-OB serum profile following the
first and 12th weekly sc injection was
similar. Following a sc PEG-OB injec-
tion, mean peak serum PEG-OB con-
centrations were achieved 72 h after
dosing, followed by a return to the ele-
vated pre-dose levels after 1 week.
TABLE 1. Subject characteristics
Placebo
(n 5 15)
PEG-OB
(n 5 15)
Body weight (kg) 108.6 6 4.6 (89.5–139.6) 107.3 6 3.4 (85.6–137.4)
BMI (kg/m2) 33.8 6 1.2 (30.3–43.7) 34.0 6 1.0 (29.3–39.7)
Age (yr) 44 6 2 (33–54) 45 6 2 (33–58)
Leptin concentration (ng/mL) 20.4 6 4.9 (2.2–47.3) 21.9 6 4.9 (5.5–41.0)
Insulin concentration (ng/mL) 21.3 6 1.5 (6.4–28.0) 19.6 6 2.6 (6.8–29.2)
Data are mean 6 SEM.
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and PEG-OB treatment groups, respectively. Total leptin se-
rum concentrations increased slightly to a new steady-state
level (24.0 ng/mL during weeks 9–12 of the study) in subjects
treated with PEG-OB, whereas total leptin concentrations fell
with weight loss in placebo-treated subjects (14.6 ng/mL
during weeks 9–12 of the study) (Fig. 2).
Body weight, body composition, and energy metabolism
The effect of PEG-OB treatment or placebo treatment on
body weight, body composition, and energy expenditure are
given in Table 2. The mean body weight change was 25.4 6
0.8 kg in all 30 subjects studied. Subjects in both the placebo
(n 5 15) and PEG-OB (n 5 15) treatment groups lost weight,
and the amount of weight loss was similar in both groups
(day 85 body weight: placebo, 102.2 6 4.1 kg, delta, 26.4 kg;
PEG-OB, 103.0 6 3.0; delta, 24.3 kg). There was no significant
difference in the delta or percent weight loss between the
PEG-OB and placebo groups (Table 2). The mean changes in
percent body fat and sleeping metabolic rate of all 30 subjects
were 21.4 6 0.4% and 20.4 6 0.07 kJ/min, respectively, and
there were no significant differences between PEG-OB and
placebo. No differences were observed in RQ between the
treatment groups. Using a technique pioneered in the clinical
trials with the lipase inhibitor orlistat, subjects were classified
as “good” losers (delta body weight at 4 weeks $2.5 kg) and
“poor” losers (delta body weight at 4 weeks ,2.5 kg) in each
treatment groups (29–31). An imbalance of the distribution
was observed with more good losers (8 of 15 or 53%) in the
placebo group than the PEG-OB group (5 of 15 or 33%).
Metabolic profile
The effect of 20 mg PEG-OB or placebo treatment on the
metabolic profile is shown in Table 3. No significant differ-
ences in serum glucose or insulin concentrations from base-
line were observed at the end of the 12-week treatment pe-
riod, and there were no differences between the treatment
groups. Insulin sensitivity (measured by the short insulin
tolerance test) also showed no significant differences be-
tween both groups before and after treatment.
Mean baseline (day 1) serum concentrations of free fatty
FIG. 2. Total serum leptin concentra-
tions following weekly sc PEG-OB dos-
ing during the study. PEG-OB was ad-
ministered sc on days 1, 8, 15, 22, 29, 36,
43, 50, 57, 64, 71, and 78. Total leptin
concentrations are mean 6 SEM. Base-
line total leptin concentrations were
20.4 6 4.9 and 21.9 6 4.9 ng/mL in the
placebo (h) and PEG-OB treatment (v)
groups, respectively. Total leptin serum
concentrations in blood samples taken
just before the next weekly dose of
PEG-OB increased to a new steady-
state level during weeks 9–12 of the
study in subjects treated with PEG-OB,
whereas total leptin concentrations fell
with weight loss in placebo-treated sub-
jects during weeks 9–12 of the study.
More frequent blood sampling occurred
after the first (day 1) and 12th weekly
(day 78) dose. Note that total leptin se-
rum profile following the first and 12th
weekly sc PEG-OB injection were sim-
ilar. Following a sc PEG-OB injection,
mean peak serum total leptin concen-
trations were achieved 72 h after dos-
ing, followed by a return to the elevated
pre-dose levels after 1 week. *, Signifi-
cant differences between the PEG-OB
and placebo groups.
TABLE 2. Effect of 12 weeks treatment with PEG-OB or placebo on body weight, body composition, and energy metabolism
Placebo (n 5 15) PEG-OB (n 5 15)
Day 1 Day 85 Delta
(day 85-day 1)
Day 1 Day 85 Delta
(day 85-day 1)
Body weight (kg) 108.6 6 4.6 102.2 6 4.1 26.4 107.3 6 3.4 103.0 6 3.0 24.3
Body fat (%) 36.7 6 1.5 33.2 6 1.7 21.8a 35.2 6 1.5 32.9 6 1.5 20.9a
24-h EE (MJ/day) 14.0 6 0.4 12.8 6 0.4 21.2b 14.1 6 0.3 13.4 6 0.3 20.7c
SMR (MJ/day) 8.3 6 0.2 7.7 6 0.2 20.6b 8.5 6 0.2 8.0 6 0.2 20.5c
RQ 0.84 6 0.002 0.85 6 0.01 20.01 0.84 6 0.001 0.84 6 0.01 0.0
Data are mean 6 SEM. For differences compared with baseline (a P , 0.05; b P , 0.001; c P , 0.01). There were no significant differences
between treatments. EE, Energy expenditure.
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acids, triglycerides, and total cholesterol were larger in the
PEG-OB group than in the placebo group. However, when the
range of the serum concentrations is considered (Table 3), no
significant differences were observed. Although larger reduc-
tions in serum concentrations of triglycerides within subjects
were observed at the end of the 12-week treatment period in the
PEG-OB treatment compared with the placebo treatment group
(PEG-OB, delta 5 20.35 6 0.15 mmol/L vs. placebo, delta 5
20.17 6 0.12 mmol/L), these differences were not statistically
significant. The change in serum tri-glycerides from baseline as
a function of body weight loss is shown in Fig. 3. Percent change
in serum triglycerides from baseline was significantly corre-
lated with the amount of body weight loss in the PEG-OB
treatment group (P , 0.01) but not in the placebo treatment
group. No significant differences in serum glycerol, LDL-
cholesterol, and HDL-cholesterol concentrations from baseline
were observed at the end of the 12-week treatment period, and
there were no differences between the treatment groups.
Safety
The most common adverse events related to PEG-OB treat-
ment are shown in Table 4. The most significant findings
were pain at the injection site and pruritis. These occurred
with similar frequency in both the placebo and the PEG-OB
groups and generally occurred only with the first or second
series of injections.
One subject in the placebo group developed a kidney stone
on study day 78. The subject was hospitalized for 2 days, and
the kidney stone was passed without intervention. This se-
rious adverse event was classified as unrelated to treatment.
The subject completed the study.
Safety data were reviewed as one composite group first and
then by treatment group. There were no clinically relevant
changes in the mean values of laboratory measurements or vital
signs during the study. No difference was detected between the
groups with regard to standard chemistry or hematology as-
sessments. The mean total serum protein was reduced (22.3%)
in the PEG-OB group, but not in the placebo group (20.5%).
However, no difference in urinary protein was observed be-
tween the groups. In summary, at the dose studied, PEG-OB
seemed to be generally well tolerated and safe.
Discussion
These results demonstrate that weekly 20-mg sc PEG-OB
administration to obese men on a hypocaloric diet led to sus-
tained serum concentration of both PEG-OB and leptin, mea-
sured just before the next dose, throughout the 12-week treat-
ment period. Mean peak serum PEG-OB concentrations were
achieved 72 h after dosing, followed by a return to the elevated
pre-dose levels after 1 week. Total leptin serum concentrations
increased to a new steady-state level in subjects treated with
PEG-OB, whereas total leptin concentrations fell with weight
loss in placebo-treated subjects. In addition, weekly 20-mg sc
PEG-OB was generally well tolerated and safe in these subjects.
No significant differences in the delta or percent weight loss,
percent body fat, or sleeping metabolic rate were observed
between the PEG-OB and placebo groups. No differences were
observed in RQ between the treatment groups. Due to the
premature termination of the study based on the interim anal-T
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ysis, the power of the study was suboptimal and it remains
unknown whether PEG-OB has no effect on weight loss.
Percent change in serum triglycerides from baseline was
significantly correlated with the amount of body weight loss
in the PEG-OB treatment group, but not in the placebo treat-
ment group. Although larger reductions in serum concen-
trations of triglycerides were observed at the end of the
12-week treatment period in the PEG-OB group compared
with the placebo treatment group, these differences were not
statistically significant. The trends in serum triglycerides are
consistent with similar changes repeatedly observed in stud-
ies in which obese rats or mice were treated with leptin at
doses that did not reduce body weight (4–6, 32). It has been
proposed by Unger et al. (33) that an important function of
leptin is to confine the storage of triglycerides to the adipo-
cytes, while limiting triglyceride storage in nonadipocytes
and to selectively mobilize fat. Together with a small but
consistent reduction in hunger ratings after overnight fasts
throughout the treatment period and a reduction in gener-
alized hunger as measured by the three-factor eating inven-
tory in the PEG-OB group (34), these trends in serum tri-
glycerides suggest that weekly 20-mg sc treatment with
PEG-OB may have biological effects in obese men.
In trials sponsored by Amgen Inc., lean and obese subjects
received multiple daily sc injections of met-leptin ranging
from 0.01–0.3 mg/kg. Significant dose-related reductions in
body fat and body weight were observed following daily sc
treatment with up to 0.30 mg/kg met-leptin for 24 weeks (9).
Mean weight loss from baseline increased with increasing
met-leptin dose in obese subjects at 24 weeks of treatment.
The most effective dose for weight and fat loss was 0.3 mg/kg
and would be equivalent to an average dose of 30 mg/week
in our 100-kg subjects. Mild and moderate injection site re-
actions were the most common adverse events reported (9).
The treatment of a young very obese girl with a mutated ob
gene, with daily sc injection of low doses of met-leptin (dose of
FIG. 3. The percent change in serum triglycerides from baseline following weekly sc PEG-OB dosing as a function of body weight loss at the
end of the study. The percent change in serum triglycerides from baseline (day 1) at the end of the 12-week treatment period (day 85) in each
subject in the placebo (E) and PEG-OB treatment (F) groups is plotted as a function of the body weight loss. Regression lines were determined
in both groups. In the placebo group, the slope was 0.2 with a P 5 0.9, whereas in the PEG-OB group, the slope was 3.9 with P 5 0.01. Thus,
percent change in serum triglycerides from baseline was significantly correlated with the amount of body weight loss in the PEG-OB treatment
group but not in the placebo treatment group. When the data points for all 30 subjects were combined, the slope of the regression line between
decrease in triglycerides (expressed as percent change from baseline) in the PEG-OB group was significantly different from the regression line
in the placebo group (analysis of covariance; P , 0.05).
TABLE 4. Most common adverse events related to PEG-OB
treatment
Event
Frequency
(no. of subjects reporting)
Placebo PEG-OB
Hematoma at injection site 5/15 3/15
Local irritation at the injection site 1/15 4/15
Pain at injection site 1/15 1/15
Itching or rash 1/15 2/15
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0.028 mg/kg of lean mass calculated to cause a circulating
concentration ;10% of what would be predicted based on her
body fat), has been reported. Daily met-leptin treatment for 12
months caused a dramatic reduction in appetite, food-seeking
behavior, food intake, and body weight (10). After 12 months
of treatment, her body weight was reduced by 16.4 kg, 95% of
which was body fat. As in the studies reported here with PEG-
OB, met-leptin treatment had no effect on metabolic rate or
energy expenditure in this girl. However, her lipid profile,
which was normal prior to treatment, was not effected by met-
leptin administration. The results of treatment of this girl with
congenital leptin deficiency (10), taken together with the results
of the Amgen trials in obese adults (9), indicate that leptin has
biological activity in at least some obese humans and that
among its activities are reductions in appetite and food intake
at low doses and reductions in body fat and body weight at the
maximal dose studied.
Other biological effects of leptin and PEG-OB observed in
animal studies were not observed in this study. Most prominent
among these were serum glucose and insulin concentrations (5,
6). We failed to observe any treatment effects on these variables
possibly due to the small sample size or 20-mg PEG-OB dose
or weekly dosing schedule. However, neither parameter was
elevated in the group of obese men enrolled in this trial. We also
failed to observe a reduction in body fat, as well as total energy
expenditure and sleeping metabolic rate (5, 6).
The steady-state concentrations of PEG-OB (200–300 ng/
mL) following weekly 20-mg sc PEG-OB were lower than the
blood levels of met-leptin associated with efficacy (13). Given
the similarities in the biological activity to reduce appetite
between weekly sc 20 mg PEG-OB (34) and daily low-dose
met-leptin in congenital leptin deficiency (10) and the dif-
ference in blood levels, it is possible that increasing the dose
of PEG-OB or altering the dosing schedule may result in
significant reductions in body fat and body weight in addi-
tion to larger decreases in appetite, hunger, food intake, and
serum triglycerides concentrations. The testing of this hy-
pothesis will be the subject of future research.
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